The company will work with medical faculties of the universities of Greifswald and Rostock to develop Dx tools for personalized, immune-based treatments.
The American Cancer Society today lowered the recommended age for screening patients at average risk for the disease to 45 from 50 years old.
A multi-region analysis of colorectal cancers suggests samples from opposite sides of a tumor can help trace early, invasiveness-related tumor characteristics.
The company said test volume rose 87 percent to 186,000 during the quarter.
Prospective panel sequencing on colorectal cancer patients picked up Lynch syndrome with sensitivity and specificity that met or exceeded gene-by-gene tests.
The company said 571,000 people were screened for colon cancer with its noninvasive Cologuard test in 2017.
Investigators identified mutation, expression, and methylation differences in colorectal polyps from individuals with or without colorectal cancer.
Two bacterial species together help feed the development of colon cancer, according to the New York Times.
Investors in Exact Sciences went on a selling spree after CellMax publicized data suggesting its test could outperform Cologuard for the early detection of colorectal cancer.
A new study suggests that Fusobacterium and other microbes may hitch a ride to metastatic sites with primary colorectal cancers, prompting tumor growth.
US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.
Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.
In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.
In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.